This is an important moment for Helsinn, as it allows us to bring an additional option to patients experiencing CINV in highly emetogenic chemotherapy treatment." Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States There is ...